EDIT

Editas Medicine, Inc.

Healthcare
Biotechnology
$414M market cap

Forecast run · Sep 17, 2026Upside rank 498 of 3,136

Model Signal

ForecastQ Daily Probabilities

53.5%

38.7%

30.3%

Analyst Consensus

Recommendation2.52/5 Hold

Last price$2.70

Price target$4.00

Implied move+48.1%

Analysts25

ForecastQ Portfolios

EDIT is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.